Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PRPH 
ProPhase Labs Inc (PRPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: PRPH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13.8
1 Year Target Price $13.8
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -57.12% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.39M USD | Price to earnings Ratio - | 1Y Target Price 13.8 |
Price to earnings Ratio - | 1Y Target Price 13.8 | ||
Volume (30-day avg) 1 | Beta -0.47 | 52 Weeks Range 0.22 - 3.00 | Updated Date 08/29/2025 |
52 Weeks Range 0.22 - 3.00 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.07 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.15 | Actual -0.11 |
Profitability
Profit Margin - | Operating Margin (TTM) -312.27% |
Management Effectiveness
Return on Assets (TTM) -28.85% | Return on Equity (TTM) -171.81% |
Valuation
Trailing PE - | Forward PE 10.09 | Enterprise Value 22089027 | Price to Sales(TTM) 2.58 |
Enterprise Value 22089027 | Price to Sales(TTM) 2.58 | ||
Enterprise Value to Revenue 3.95 | Enterprise Value to EBITDA 2.45 | Shares Outstanding 41541200 | Shares Floating 38222063 |
Shares Outstanding 41541200 | Shares Floating 38222063 | ||
Percent Insiders 7.99 | Percent Institutions 6.57 |
Upturn AI SWOT
ProPhase Labs Inc
Company Overview
History and Background
ProPhase Labs, Inc. (PRPH) was originally incorporated in 1987. The company has evolved from a provider of over-the-counter health products to focusing on diagnostics, genomics, and dietary supplements.
Core Business Areas
- Diagnostic Services: Provides CLIA-certified COVID-19 testing and other diagnostic services through its Nebula Genomics division.
- Genomics Services: Offers whole genome sequencing and personalized health insights through Nebula Genomics.
- Dietary Supplements: Sells dietary supplements, particularly through its BE-ALIVE brand and Legend brands. Also manufactures and distributes over-the-counter medicines through its TKC Health division.
Leadership and Structure
Ted Karkus is the CEO. The company operates with distinct divisions for diagnostics, genomics, and consumer products.
Top Products and Market Share
Key Offerings
- COVID-19 Testing: Offers various COVID-19 testing services. Market share is highly variable and depends on testing demand but peaked in prior years. Competitors include Labcorp (LH), Quest Diagnostics (DGX) and many smaller providers.
- Nebula Genomics Whole Genome Sequencing: Provides whole genome sequencing with personalized health insights. The market share is smaller compared to traditional genetic testing. Competitors include 23andMe, AncestryDNA, and others offering genetic testing services.
- BE-ALIVE Dietary Supplements: Offers a range of dietary supplements focused on immune support and overall wellness. Market share is fragmented with numerous competitors. Sales revenue not publically available. Competitors include nutraceutical companies such as GNC, Vitamin Shoppe (VSI) and Herbalife (HLF).
Market Dynamics
Industry Overview
The diagnostics and genomics industry is characterized by rapid innovation, increasing demand for personalized medicine, and evolving regulatory landscape. The dietary supplement market is large and competitive, driven by consumer health awareness.
Positioning
ProPhase Labs is positioned as a player in both the diagnostics/genomics and consumer health spaces. It aims to leverage its testing infrastructure for broader genomic services. Competitive advantages include its diagnostic infrastructure and Nebula Genomics offering.
Total Addressable Market (TAM)
TAM for diagnostics is estimated in the hundreds of billions globally. Genomics is a smaller but rapidly growing segment. Dietary supplements are also a large global market estimated at around $200 billion. PRPH is positioning itself for a small piece of each of these markets.
Upturn SWOT Analysis
Strengths
- Established diagnostic infrastructure
- Nebula Genomics offering
- Diverse revenue streams (diagnostics, genomics, supplements)
- Experienced leadership
Weaknesses
- Dependence on COVID-19 testing revenue
- Limited brand recognition compared to major competitors
- Relatively small size and resources
- Inconsistent profitability
Opportunities
- Expansion of genomic services beyond COVID-19
- Strategic partnerships and acquisitions
- Growth in personalized medicine market
- Increased demand for at-home testing
Threats
- Decline in COVID-19 testing demand
- Increased competition in genomics and supplements
- Regulatory changes
- Economic downturn
Competitors and Market Share
Key Competitors
- LH
- DGX
- 23andMe
- VSI
- HLF
Competitive Landscape
ProPhase Labs faces intense competition from larger, more established players in both the diagnostics and consumer health markets. Success depends on niche differentiation and effective marketing.
Growth Trajectory and Initiatives
Historical Growth: Growth has been significantly impacted by the fluctuating demand for COVID-19 testing. Post-COVID, growth depends on the success of the Nebula Genomics and supplement businesses.
Future Projections: Future growth projections are uncertain and depend on diversification efforts and market conditions. Analyst estimates are variable and require current data.
Recent Initiatives: Focus on expanding Nebula Genomics and dietary supplement offerings. Exploring strategic partnerships to expand market reach.
Summary
ProPhase Labs is a small company attempting to pivot from COVID-19 testing to genomics and supplements. While its diagnostics infrastructure is a strength, the company faces stiff competition from larger firms. It needs to grow Nebula Genomics and its supplement lines significantly and diversify away from dependence on COVID-19 testing. Future performance is uncertain.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q)
- Press releases
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ProPhase Labs Inc
Exchange NASDAQ | Headquaters Garden City, NY, United States | ||
IPO Launch date 1997-01-16 | Chairman & CEO Mr. Ted William Karkus | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 96 | Website https://www.prophaselabs.com |
Full time employees 96 | Website https://www.prophaselabs.com | ||
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.